Literature DB >> 9203172

Effect of interleukin-8 on glomerular sulfated compounds and albuminuria.

E H Garin1, L West, W Zheng.   

Abstract

To evaluate the effect of interleukin-8 (IL8) on glomerular basement membrane (GBM) sulfated compounds and albuminuria, we infused IL8 in 1% bovine serum albumin (BSA) for 5 days into the left renal artery of Holtzman male rats at the rate of 10 microliters/h using an osmotic pump. Control rats received 1% BSA. A significant increase in urinary albumin/creatinine ratio was seen on the last day of IL8 infusion (0.38 +/- 0.11, mean +/- SEM) when compared with albumin/creatinine ratio prior to infusion (0.19 +/- 0.04, P = 0.04). No significant differences in urinary albumin excretion prior to and after infusion of 1% BSA were observed. On the last day of infusion, rats were injected with 35sulfate (1.0 mCi/200 g body weight) intraperitoneally and killed after 8 h. Glomeruli were isolated and GBM obtained. After 5 days of IL8 administration, there was a significant increase in 35sulfate uptake by GBM of the infused kidney (76 +/- 10 cpm/dry glomerular weight, mean +/- SEM) compared with the uptake seen in the contralateral kidney (53 +/- 9, P = 0.05). The in vivo infusion of IL8 increased the 35sulfate uptake by GBM and augmented the urinary albumin/creatinine ratio, suggesting that IL8 may induce albuminuria by altering the metabolism of the GBM sulfated compounds. This hypothesis needs to be confirmed by studies on glomerular charge selectivity and GBM anionic sites during the course of the infusion. Moreover, the persistence of the effect needs to be evaluated by prolonging the infusion for more than 5 days.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9203172     DOI: 10.1007/s004670050276

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  8 in total

Review 1.  Role of TWEAK in lupus nephritis: a bench-to-bedside review.

Authors:  Jennifer S Michaelson; Nicolas Wisniacki; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2012-06-22       Impact factor: 7.094

2.  Cytokine dynamics in a 14-year-old girl with tubulointerstitial nephritis and uveitis syndrome.

Authors:  Jun Aoyagi; Takahiro Kanai; Takane Ito; Jun Odaka; Takashi Saito; Mariko Y Momoi
Journal:  CEN Case Rep       Date:  2013-06-09

Review 3.  Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanisms.

Authors:  Gabriel Cara-Fuentes; William L Clapp; Richard J Johnson; Eduardo H Garin
Journal:  Pediatr Nephrol       Date:  2016-07-06       Impact factor: 3.714

Review 4.  A conceptual framework for the molecular pathogenesis of progressive kidney disease.

Authors:  H William Schnaper; Susan C Hubchak; Constance E Runyan; James A Browne; Gal Finer; Xiaoying Liu; Tomoko Hayashida
Journal:  Pediatr Nephrol       Date:  2010-03-30       Impact factor: 3.714

Review 5.  Corticosteroid-resistant nephrotic syndrome with focal and segmental glomerulosclerosis : an update of treatment options for children.

Authors:  Jochen H H Ehrich; Lars Pape; Mario Schiffer
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 6.  A case of unfulfilled expectations. Cytokines in idiopathic minimal lesion nephrotic syndrome.

Authors:  Carlos E Araya; Clive H Wasserfall; Todd M Brusko; Wei Mu; Mark S Segal; Richard J Johnson; Eduardo H Garin
Journal:  Pediatr Nephrol       Date:  2006-03-07       Impact factor: 3.714

Review 7.  Bench-to-bedside review: Ventilation-induced renal injury through systemic mediator release--just theory or a causal relationship?

Authors:  Jan Willem Kuiper; Rosanna Vaschetto; Francesco Della Corte; Frans B Plötz; A B Johan Groeneveld
Journal:  Crit Care       Date:  2011-08-16       Impact factor: 9.097

Review 8.  Molecular Mechanisms of Proteinuria in Minimal Change Disease.

Authors:  Shrey Purohit; Federica Piani; Flor A Ordoñez; Carmen de Lucas-Collantes; Colin Bauer; Gabriel Cara-Fuentes
Journal:  Front Med (Lausanne)       Date:  2021-12-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.